WO1996009075A1 - Procede de traitement d'affections malignes - Google Patents

Procede de traitement d'affections malignes Download PDF

Info

Publication number
WO1996009075A1
WO1996009075A1 PCT/RU1995/000195 RU9500195W WO9609075A1 WO 1996009075 A1 WO1996009075 A1 WO 1996009075A1 RU 9500195 W RU9500195 W RU 9500195W WO 9609075 A1 WO9609075 A1 WO 9609075A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
days
month
day
drug
Prior art date
Application number
PCT/RU1995/000195
Other languages
English (en)
Russian (ru)
Inventor
Viktor Vladimirovich Keshelava
Original Assignee
Keshelava Viktor V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keshelava Viktor V filed Critical Keshelava Viktor V
Priority to AU34882/95A priority Critical patent/AU3488295A/en
Publication of WO1996009075A1 publication Critical patent/WO1996009075A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1258—Pills, tablets, lozenges

Definitions

  • the task posed is solved in that, in the case of the use of an easy-to-sing, in addition to the introduction of a radioactive nuclide 59 Ges with an induced activity of 0.8 mcg for a single dose of the drug, a safe preparation, is administered once a day after a month of treatment, after a month of treatment
  • a weekly annual supply (GWP) for 59GH is made
  • Diagnosis is an immune disease with a temporal lobe of the lower brain. A thorough treatment has been made. for the course of ceremonies, radiation therapy for the main brain of the SDS 44 g. ⁇ connection ⁇ g ⁇ essi ⁇ vaniem ⁇ ezni, ⁇ azheniem ⁇ av ⁇ y gemis ⁇ e ⁇ y and zadneg ⁇ ⁇ ga ⁇ v ⁇ g ⁇ zhelud ⁇ ch ⁇ a, nacha ⁇ treatment ⁇ adi ⁇ a ⁇ ivnym nu ⁇ id ⁇ m 59 Ge, navedenn ⁇ y a ⁇ ivn ⁇ s ⁇ yu 0.8 m ⁇ i on ⁇ dnu d ⁇ zu ⁇ e ⁇ a ⁇ a ⁇ a ⁇ s ⁇ eme ⁇ echeniya, ⁇ isann ⁇ y in ⁇ ime ⁇ e ⁇ .
  • Diagnosis disease ⁇ 4 ⁇ 0 ⁇ 0.
  • the company could not be removed due to the widespread process.
  • the treatment was carried out 59 G with an induced activity of 0.8 mg for one dose of the drug at the time of treatment described in the case of ⁇ .
  • the treatment must be stopped at the last end of the course of the first course of treatment. Conducted - removal of the kidney.
  • After two months 8 For information on the subject of publication, please refer to the scheme described in this article. After a year, it is a good condition that it is in good condition.
  • Diagnosis Esophagus ⁇ .
  • This product is intended for use in the care of children, as well as small arms, food, handicap and other. Treatment with this method can be produced as it is, both alone and in combination with well-known methods of the treatment of the drug. Taking into account

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Le procédé proposé de traitement d'affections malignes consiste à utiliser un nucléide radioactif Fe59 présentant une activité induite de 0,8 mCi par dose de la préparation sous forme de comprimé, 50 comprimés étant absorbés pendant une durée de six mois. Le traitement de l'invention est appliqué soit indépendamment soit simultanément avec d'autres procédés de traitement du cancer. Etant donné que les cellules tumorales tendent à accumuler des composés de fer, le radionucléide Fe59, d'une activité induite de 0,8 mCi par dose, peut être utilisé en tant qu'agent de diagnostic en cancérologie.
PCT/RU1995/000195 1994-09-21 1995-09-04 Procede de traitement d'affections malignes WO1996009075A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU34882/95A AU3488295A (en) 1994-09-21 1995-09-04 Method of treating malignant conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU94035764 1994-09-21
RU94035764A RU2053776C1 (ru) 1994-09-21 1994-09-21 Способ лечения онкологического заболевания

Publications (1)

Publication Number Publication Date
WO1996009075A1 true WO1996009075A1 (fr) 1996-03-28

Family

ID=20160826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1995/000195 WO1996009075A1 (fr) 1994-09-21 1995-09-04 Procede de traitement d'affections malignes

Country Status (3)

Country Link
AU (1) AU3488295A (fr)
RU (1) RU2053776C1 (fr)
WO (1) WO1996009075A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2174015C1 (ru) * 2000-11-21 2001-09-27 Кешелава Виктор Владимирович Препарат для лечения онкологического заболевания, способ его получения и применение

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5006329A (en) * 1988-01-22 1991-04-09 Cadema Medical Products, Inc. Radioactive tagged compounds and method for the treatment of metastatic bone cancer
WO1991016075A1 (fr) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Techniques de traitement de la moelle osseuse
WO1993000927A1 (fr) * 1991-07-12 1993-01-21 Antisoma Limited Traitement du cancer
WO1994004189A1 (fr) * 1992-08-25 1994-03-03 Medac Gesellschaft Fur Klinische Spezialpräparate Mbh Anticorps/radio-isotope conjugues de diagnostic et/ou therapie de tumeurs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5006329A (en) * 1988-01-22 1991-04-09 Cadema Medical Products, Inc. Radioactive tagged compounds and method for the treatment of metastatic bone cancer
WO1991016075A1 (fr) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Techniques de traitement de la moelle osseuse
WO1993000927A1 (fr) * 1991-07-12 1993-01-21 Antisoma Limited Traitement du cancer
WO1994004189A1 (fr) * 1992-08-25 1994-03-03 Medac Gesellschaft Fur Klinische Spezialpräparate Mbh Anticorps/radio-isotope conjugues de diagnostic et/ou therapie de tumeurs

Also Published As

Publication number Publication date
RU2053776C1 (ru) 1996-02-10
RU94035764A (ru) 1997-03-27
AU3488295A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
Becker One century of radon therapy
Nakayama et al. The history of multimodal treatment of Wilms’ tumor
Nielsen et al. Influence of thermotolerance on the interaction between hyperthermia and radiation in a solid tumour in vivo
Wowra et al. Incidence of late radiation necrosis with transient mass effect after interstitial low dose rate radiotherapy for cerebral gliomas
Johnson et al. Handbook of oncology nursing
Juillard et al. A phase I study of active specific intralymphatic immunotherapy (ASILI)
Wang et al. Evaluation of endoscopic-ultrasound-guided celiac ganglion irradiation with iodine-125 seeds: a pilot study in a porcine model
WO1996009075A1 (fr) Procede de traitement d'affections malignes
Hayter The clinic as laboratory: The case of radiation therapy, 1896-1920
Tatum et al. Acute cocain poisoning: Preliminary report of an experimental study
Early et al. Use of therapeutic radionuclides in medicine
WO1992013563A1 (fr) Preparation antitumorale et son procede de production
Crabb et al. Metals and Life Chapter 9
Fleck et al. Coccidian-like nature of Toxoplasma gondii.
Priestman Coping with Radiotherapy
Morgan Fast neutron therapy
Dolinsky et al. Palliative radiation therapy in oncology
Green et al. Radiotherapy: its nature 6
Donev et al. Professor Anastas Kocarev, First Macedonian Oncologist with Worldwide Reputation and Pioneer in Cancer Diagnostics and Treatment with Radium
WO2002041923A1 (fr) Preparation destinee au traitement d'une affection oncologique et procedes de fabrication et d'application
RU2243766C1 (ru) Способ лечения рецидивов рака шейки матки
Bidin et al. The Ruqyah Syar’iyyah Verses as A Breast Cancer Therapy: A Preliminary Evaluation on Breast Cancer Cell Line Michigan Cancer Foundation (MCF-7)
Demopoules Special diets said to inhibit melanoma growth
DeVita Cancer Treatment
RU2163811C1 (ru) Способ лечения рака iii-iv стадии

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NO NZ PL PT RO RU SD SE SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642